Annual CFI
-$382.60 K
+$67.90 K+15.07%
December 31, 2023
Summary
- As of February 7, 2025, BGLC annual cash flow from investing activities is -$382.60 thousand, with the most recent change of +$67.90 thousand (+15.07%) on December 31, 2023.
- During the last 3 years, BGLC annual CFI has fallen by -$1.70 million (-128.98%).
- BGLC annual CFI is now -128.98% below its all-time high of $1.32 million, reached on December 1, 2020.
Performance
BGLC Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
-$183.10 K
-$266.20 K-320.34%
September 30, 2024
Summary
- As of February 7, 2025, BGLC quarterly cash flow from investing activities is -$183.10 thousand, with the most recent change of -$266.20 thousand (-320.34%) on September 30, 2024.
- Over the past year, BGLC quarterly CFI has dropped by -$266.20 thousand (-320.34%).
- BGLC quarterly CFI is now -110.69% below its all-time high of $1.71 million, reached on March 1, 2020.
Performance
BGLC Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
-$89.70 K
+$177.60 K+66.44%
September 30, 2024
Summary
- As of February 7, 2025, BGLC TTM cash flow from investing activities is -$89.70 thousand, with the most recent change of +$177.60 thousand (+66.44%) on September 30, 2024.
- Over the past year, BGLC TTM CFI has increased by +$177.60 thousand (+66.44%).
- BGLC TTM CFI is now -105.19% below its all-time high of $1.73 million, reached on September 1, 2020.
Performance
BGLC TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
BGLC Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +15.1% | -320.3% | +66.4% |
| 3 y3 years | -129.0% | -3490.2% | +65.3% |
| 5 y5 years | -640.0% | -3490.2% | +65.3% |
BGLC Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +22.0% | -320.3% | +49.2% | -125.9% | +83.8% |
| 5 y | 5-year | -129.0% | +22.0% | -110.7% | +56.0% | -105.2% | +89.2% |
| alltime | all time | -129.0% | +22.0% | -110.7% | +56.0% | -105.2% | +89.2% |
BioNexus Gene Lab Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$183.10 K(-320.3%) | -$89.70 K(-66.4%) |
| Jun 2024 | - | $83.10 K(+244.8%) | -$267.30 K(-24.4%) |
| Mar 2024 | - | $24.10 K(-274.6%) | -$353.50 K(-7.6%) |
| Dec 2023 | -$382.60 K(-15.1%) | -$13.80 K(-96.2%) | -$382.70 K(-8.6%) |
| Sep 2023 | - | -$360.70 K(>+9900.0%) | -$418.80 K(+954.9%) |
| Jun 2023 | - | -$3100.00(-39.2%) | -$39.70 K(-84.6%) |
| Mar 2023 | - | -$5100.00(-89.8%) | -$258.40 K(-42.6%) |
| Dec 2022 | -$450.50 K(-8.2%) | -$49.90 K(-371.2%) | -$450.40 K(-5.5%) |
| Sep 2022 | - | $18.40 K(-108.3%) | -$476.80 K(-13.9%) |
| Jun 2022 | - | -$221.80 K(+12.5%) | -$553.80 K(+41.3%) |
| Mar 2022 | - | -$197.10 K(+158.3%) | -$391.90 K(-20.1%) |
| Dec 2021 | -$490.60 K | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | - | -$76.30 K(+30.2%) | -$490.60 K(-40.9%) |
| Sep 2021 | - | -$58.60 K(-2.2%) | -$830.80 K(+8.2%) |
| Jun 2021 | - | -$59.90 K(-79.7%) | -$767.80 K(+11.6%) |
| Mar 2021 | - | -$295.80 K(-29.0%) | -$688.00 K(-152.1%) |
| Dec 2020 | $1.32 M(<-9900.0%) | -$416.50 K(-9565.9%) | $1.32 M(-23.7%) |
| Sep 2020 | - | $4400.00(-77.9%) | $1.73 M(+0.1%) |
| Jun 2020 | - | $19.90 K(-98.8%) | $1.73 M(+0.8%) |
| Mar 2020 | - | $1.71 M(<-9900.0%) | $1.71 M(<-9900.0%) |
| Dec 2019 | -$12.80 K(-75.2%) | -$7100.00(-302.9%) | -$12.80 K(+124.6%) |
| Sep 2019 | - | $3500.00(-35.2%) | -$5700.00(-38.0%) |
| Jun 2019 | - | $5400.00(-137.0%) | -$9200.00(-37.0%) |
| Mar 2019 | - | -$14.60 K | -$14.60 K |
| Dec 2018 | -$51.70 K | - | - |
FAQ
- What is BioNexus Gene Lab annual cash flow from investing activities?
- What is the all time high annual CFI for BioNexus Gene Lab?
- What is BioNexus Gene Lab annual CFI year-on-year change?
- What is BioNexus Gene Lab quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for BioNexus Gene Lab?
- What is BioNexus Gene Lab quarterly CFI year-on-year change?
- What is BioNexus Gene Lab TTM cash flow from investing activities?
- What is the all time high TTM CFI for BioNexus Gene Lab?
- What is BioNexus Gene Lab TTM CFI year-on-year change?
What is BioNexus Gene Lab annual cash flow from investing activities?
The current annual CFI of BGLC is -$382.60 K
What is the all time high annual CFI for BioNexus Gene Lab?
BioNexus Gene Lab all-time high annual cash flow from investing activities is $1.32 M
What is BioNexus Gene Lab annual CFI year-on-year change?
Over the past year, BGLC annual cash flow from investing activities has changed by +$67.90 K (+15.07%)
What is BioNexus Gene Lab quarterly cash flow from investing activities?
The current quarterly CFI of BGLC is -$183.10 K
What is the all time high quarterly CFI for BioNexus Gene Lab?
BioNexus Gene Lab all-time high quarterly cash flow from investing activities is $1.71 M
What is BioNexus Gene Lab quarterly CFI year-on-year change?
Over the past year, BGLC quarterly cash flow from investing activities has changed by -$266.20 K (-320.34%)
What is BioNexus Gene Lab TTM cash flow from investing activities?
The current TTM CFI of BGLC is -$89.70 K
What is the all time high TTM CFI for BioNexus Gene Lab?
BioNexus Gene Lab all-time high TTM cash flow from investing activities is $1.73 M
What is BioNexus Gene Lab TTM CFI year-on-year change?
Over the past year, BGLC TTM cash flow from investing activities has changed by +$177.60 K (+66.44%)